Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the importance of conducting prospective randomized studies in hematopoietic stem cell transplantation (HSCT) in Europe, highlighting the challenges in setting up such clinical trials. Changes in clinical practice in hematological oncology are driven by data from prospective studies. However, there are currently very few patients enrolled in prospective studies evaluating strategies to improve HSCT delivery and patient outcomes. In recent years, there have been efforts to improve this infrastructure in the UK, notably by setting up a transplantation trial platform, opening new transplant centers, and setting up a number of prospective studies exploring strategies to improve patient outcomes after transplantation. Prof. Craddock also describes the aims of the Accelerating Clinical Trials in the EU (ACT EU) initiative and talks on the challenges around setting up large prospective randomized studies in Europe which mainly include regulatory and funding issues. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть